Healthcare Industry News: Listeria monocytogenes
News Release - October 12, 2010
Dr. Robert Petit Joins Advaxis as V.P. of Clinical OperationsFormer Director of US Clinical Strategy for Ipilimumab at BMS
NORTH BRUNSWICK, N.J.--(Healthcare Sales & Marketing Network)-- Advaxis, Inc., (OTCBB:ADXS.ob ), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, appoints Dr. Robert Petit, PhD, to the newly created position of vice president of Clinical Operations and Medical Affairs, effective October 11, 2010. Dr. Petit will report to Dr. John Rothman, EVP of Science and Operations.
Advaxis Chairman/CEO Thomas A. Moore commented, “Dr. Petit joins Advaxis from Bristol Myers Squibb (NYSE: BMY) where he was the U.S. Medical Strategy Lead for the Ipilimumab program, director of Medical Strategy for New Oncology Products, and director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as vice president of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert is an excellent fit for Advaxis.”
Dr. Petit has 23 years’ experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV.
Dr Robert Petit stated, “I am delighted to join Advaxis. I have always believed in the potential of immunotherapy. Recent clinical successes have been achieved with therapeutic cancer vaccines and also with agents that can overcome immune suppression to enhance immunologic control of disease. Advaxis has technology that combines these activities in a single therapy, specifically targeting diseased cells while simultaneously heightening the immune attack. The Advaxis platform has demonstrated a good safety/side effect profile to date. I look forward to working with John in leading their very strong clinical program.”
“Robert has had significant FDA experience and has contributed to five NDA/BLA filings,” said Advaxis EVP of Science & Operations Dr. John Rothman. “He co-founded immunotherapy and autologous transplant programs at St. Luke’s Medical Center in Milwaukee, WI, was an assistant professor at the University of Wisconsin and worked with Otsuka Pharmaceuticals, Pharmacia, Aesgen and MGI Pharma prior to his tenure at Bristol Myers Squibb. He has developed numerous commercial agents in academic, experimental and executive scientific roles and has experience in all aspects of the type of immunologic and oncologic drug development being conducted by Advaxis.
“Dr. Petit will be managing our HPV program four phase II human clinical trials and two animal clinical programs in 2010. We will be adding two additional agents with new clinical programs 2011. This work will encompass many different diseases including cervix, breast, brain, prostate and other cancers. I welcome Dr. Petit to our team and the exciting work ahead. We are confident Dr. Petit will make a great contribution to the management of our rapidly expanding international clinical program, and our relationships with the FDA, academic and government research collaborations, and thought leaders worldwide,” concluded Dr. Rothman.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK and the Department of Homeland Security. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.